Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIFree Report) in a research report report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Down 2.9 %

Brainstorm Cell Therapeutics stock opened at $0.44 on Tuesday. The firm’s 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.40. The firm has a market capitalization of $31.05 million, a PE ratio of -1.38 and a beta of 0.43. Brainstorm Cell Therapeutics has a 1-year low of $0.13 and a 1-year high of $2.91.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. Research analysts forecast that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIFree Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Further Reading

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.